A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Phase 2

Completed

• Conditions: Diffuse Large B-cells Non-Hodgkin Lymphoma
• Interventions: Drug: Rituximab-Dexamethasone-Lenalidomide

• Registration Number: NCT02955823
• Lead Sponsor: Fondazione Italiana Linfomi - ETS

Brief Summary

A phase II study to evaluate the combination of Lenalidomide and Rituximab as front line therapy for the treatment of elderly frail patients evaluated in CGA with Diffuse Large B-cells non-Hodgkin Lymphoma.

Detailed Description

This is a prospective, multicenter, single arm, phase II trial in elderly patients (≥ 70 years) affected by DLBCL defined as frail according to CGA and previously untreated.

The primary endpoint is to evaluate the efficacy of the R2 (Revlimid+Rituximab) combination in first line DLBCL patients not candidate for the standard R-CHOP (or R-CHOP like) treatments due to the frail status.

Study Timeline

• Study Start: 2016-09
• Study First Submitted: 2016-11-02
• Study First Submitted QC: 2016-11-02
• Study First Posted: 2016-11-04
• Primary Completion: 2020-09-22
• Study Completion: 2022-11-24
• Status Verified: 2022-12
• Last Update Submitted: 2022-12-22
• Last Update Posted: 2022-12-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

1. Histologically proven CD20 positive Diffuse Large B-cell Lymphoma according to WHO classification (local pathologist)

2. Age ≥ 70 years

3. Previously untreated

4. CGA assessment performed before starting treatment

5. FRAIL patients defined as follows

   Age > 80 years (with UNFIT profile):

   ADL ≥ 5 residual functions and/or IADL ≥ 6 residual functions and/or CIRS: 0 comorbidity of grade 3-4 and 5-8 comorbidities of grade 2

   Age < 80 (ONLY one of the following criteria):

   ADL ≤ 4 residual functions IADL ≤ 5 residual functions CIRS: 1 comorbidity of grade 3-4 or > 8 comorbidities of grade 2

6. Ann Arbor Stage I - IV (Appendix F)

7. At least one bi-dimensionally measurable lesion defined as > 1.5 cm in its largest dimension on CT scan

8. ECOG performance status of 0- 3 (Appendix E)

9. No active hepatitis C virus (HCV) infection. In case of HCV positivity HCV-RNA is required. Only patients with HCV-RNA negative are accepted.

10. Adequate hematologic function (unless caused by bone marrow infiltrate), defined as follows:

    • Hemoglobin > 10 g/dL
    • WBC > 2500/mmc with PMN > 1000/ mmc
    • Platelets count ≥ 75000/mmc
    • Creatinine clearance ≥ 10 mL/min

11. Ability and willingness to comply with the study protocol procedure

12. Life expectancy > 6 months

13. Patients must give written informed consent.

14. Male subjects must practice complete abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 28 days following investigational product discontinuation, even if he has undergone a successful vasectomy.

Exclusion Criteria

1. Histological diagnosis different from CD20 positive Diffuse Large B-cell Lymphoma are excluded.
2. Previous exposure to cytotoxic agents
3. Suspect or clinical evidence of CNS involvement by lymphoma
4. Contraindication to the use of Rituximab or of Lenalidomide
5. HBsAg positivity; HBsAg-negative patients with anti-HBc antibody can be enrolled if Hepatitis B Virus (HBV)-DNA are negative and antiviral treatment with Lamivudine or Tenofir is provided.
6. HIV positivity
7. Active herpes zoster infection; previously infected patients is accepted only with concomitant treatment with Valacyclovir.
8. Any history of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer
9. AST /ALT > 2 x UNL; bilirubin > 2 x UNL; serum creatinine > 2.5 mg /dL
10. Creatinine clearance < 10 mL/min
11. Evidence of any severe active acute or chronic infection
12. Severe cardiac dysfunction (NYHA grade III-IV)
13. Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
14. Absence of caregivers in non-autonomous patients

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1 arm for all patient: Ritux-Dexame-Lena	Rituximab-Dexamethasone-Lenalidomide	Rituximab-Dexamethasone-Lenalidomide

Primary Outcome Measures

Name	Time	Method
ORR	48 months	Overall response rate (ORR) is defined as the proportion of patients with complete and partial response respectively according to Cheson 2014 (Appendix K).; The ORR rate will be evaluated both on assessed patients and on all treated patients, considering patients without a response assessment (due to any reason) as non-responders.; Response of R2 will be calculated for the EP according to Response Criteria for non-Hodgkin lymphoma (NHL) with CT scan; Cheson 2014; patients will be categorized into Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD), Non Responders (NR).
Safety: clinical relevant toxicity	48 months	Clinical relevant toxicity, defined as the proportion of patients experiencing a grade 3 or greater non haematological toxicity.

Secondary Outcome Measures

Name	Time	Method
CR	48 months	1) Complete response rate (CR) according to Response Criteria for non-Hodgkin lymphoma (NHL) with CT scan; Cheson 2014.
OS	54 months	2) Overall Survival (OS) will be defined as the time between the date of enrolment and the date of death from any cause. Patients who have not died at the time of the final analysis and patients who are lost to follow up will be censored at the date of the last contact.
PFS	54 months	3) Progression Free Survival (PFS) will be defined as the time between the date of enrolment and the date of disease progression, relapse or death from any cause. Responding patients, patients who are lost to follow up, who withdrawal the consent or drop-out due to adverse event will be censored at their last assessment date. Patients died due to tumor will be considered in progression. Patients died for any other cause will be censored to the death date.; Time to event data (PFS, OS) will be estimated using the Kaplan-Meier method. The curves will be plotted and the 95% confidence interval for median time will be calculated.
EFS	54 months	4) Event-Free Survival (EFS), (time to treatment failure) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death). Responding patients, patients who are lost to follow up, who withdrawal the consent or drop-out due to adverse event will be censored at their last assessment date. Patients died due to tumor will be considered in progression. Patients died for any other cause will be censored to the death date.
Quality of life	54 months	5) Patients will assess their health-related quality of life (HRQoL) using two validated questionnaires: the Functional Assessment of Cancer Therapy for Lymphoma (FACT-Lym) and the Quality of life (EORTC-QLQ-C30). Items for inclusion in the lymphoma subscale were selected on the basis of symptom relevance, disease specificity, and clinical relevance.

Trial Locations

Locations (18)

A.O. C. Panico - U.O.C Ematologia e Trapianto; 🇮🇹 Tricase, Lecce, Italy

AOU di Parma - U.O. Complessa di Ematologia; 🇮🇹 Parma, Italy

Ospedale delle Croci - Ematologia; 🇮🇹 Ravenna, Italy

Azienda Ospedaliero - Universitaria Policlinico di Modena - Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica; 🇮🇹 Modena, Italy

Policlinico Universitario Campus Bio-Medico - Area Ematologia Trapianto Cellule Staminali Medicina Trasfusionale e Terapia cellulare; 🇮🇹 Roma, Italy

Ospedale ULSS 6 di Vicenza - Ematologia; 🇮🇹 Vicenza, Italy

IRCCS AOU S. Martino - IST - Clinica Ematologica; 🇮🇹 Genova, Italy

Azienda Ospedali Riuniti Papardo-Piemonte - S.C. Ematologia; 🇮🇹 Messina, Italy

Clinica di Ematologia A.O.Universitaria Ospedali Riuniti, Ancona; 🇮🇹 Ancona, Italy

Ospedale Guglielmo da Saliceto - U.O.Ematologia; 🇮🇹 Piacenza, Italy

Ospedale degli Infermi di Rimini - U.O. di Ematologia; 🇮🇹 Rimini, Italy

Univ. Perugia Sede Terni - Oncoematologia; 🇮🇹 Terni, Italy

Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS - Ematologia; 🇮🇹 Reggio nell'Emilia, Reggio Emilia, Italy

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia; 🇮🇹 Meldola, Forlì-Cesena, Italy

Ospedale Dell'Angelo - U.O. Ematologia; 🇮🇹 Mestre, Venezia, Italy

A.O. Spedali Civili di Brescia - Ematologia; 🇮🇹 Brescia, Italy

ASST Grande Ospedale Metropolitano Niguarda; 🇮🇹 Milano, Italy

I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1; 🇮🇹 Padova, Italy